OncoMatch/Clinical Trials/NCT04305691
Trial of Ixazomib for Kaposi Sarcoma
Is NCT04305691 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ixazomib Citrate for kaposi sarcoma.
Treatment: Ixazomib Citrate — This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: proteasome inhibitor (ixazomib)
Participants who have had prior treatment of Kaposi sarcoma with a proteasome inhibitor within the last 2 years or with ixazomib at any time
Cannot have received: chemotherapy
Participants who have had chemotherapy ... within 4 weeks (6 weeks for nitrosoureas or mitomycin C) before entering the study
Cannot have received: radiotherapy
Participants who have had ... radiotherapy within 4 weeks ... before entering the study
Lab requirements
Blood counts
Absolute neutrophil count >= 1,000/mm^3; Hemoglobin > 8 g/dL; Platelets >= 75,000/mm^3 (within 21 days before enrollment). Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before study enrollment
Kidney function
Serum creatinine within normal institutional limits; or, creatinine clearance >= 30 mL/min (Cockcroft-Gault Equation, within 21 days before enrollment)
Liver function
Total bilirubin <= 1.5 x ULN (within 21 days before enrollment); if elevated bilirubin is secondary to indinavir or atazanavir therapy, then subjects allowed without any limit on total bilirubin if direct bilirubin is normal
Cardiac function
Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have NYHA Functional Classification 2B or better within 6 months before enrollment
Absolute neutrophil count: >= 1,000/mm^3 (within 21 days before enrollment); Hemoglobin: > 8 g/dL (within 21 days before enrollment); Platelets: >= 75,000/mm^3 (within 21 days before enrollment). Platelet transfusions to help participants meet eligibility criteria are not allowed within 3 days before study enrollment; Total bilirubin <= 1.5 x ULN (within 21 days before enrollment); If the elevated bilirubin is felt to be secondary to indinavir or atazanavir therapy, then subjects will be allowed on protocol without any limit on the total bilirubin if the direct bilirubin is normal; Serum creatinine levels within normal institutional limits; or, creatinine clearance >= 30 mL/min (as calculated per the Cockcroft-Gault Equation (within 21 days before enrollment); Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification within 6 months before study enrollment. To be eligible for this trial, participants must be class 2B or better within 6 months before enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego · San Diego, California
- Zuckerberg San Francisco General Hospital · San Francisco, California
- University of Miami Miller School of Medicine · Miami, Florida
- University of Illinois Cancer Center · Chicago, Illinois
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify